Novozymes’ ten-year high: Biosolutions drive double-digit growth in a volatile market

26 Jan 2023 — Enzymes manufacturer Novozymes has forecasted an outlook of between 4% to 7% for the 2023 financial year, having ended 2022 strong with 11% sales growth in Q4 despite a strained market. The company’s sales are the highest in a decade. 

Toward the end of 2022, Novozymes acquired Chr. Hansen to expand its portfolio in the nutrition industry. The merger resulted in a US$12.3 billion deal, writing history as the largest Danish merger on record and will close by the end of this year.